Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JNJ-39220675
- Development stage
- Phase 2
- Lead developer
- Janssen Research & Development
- Modality
- Small Molecules
- Administration
- Oral, Subcutaneous (preclinical)
01
Overview
JNJ-39220675 is a small molecule investigational drug developed as a selective histamine H3 receptor antagonist. It is an aryloxypyridine amide that readily penetrates the blood-brain barrier and exhibits high affinity for the histamine H3 receptor. The compound was primarily investigated for the treatment of allergic rhinitis and has also been studied preclinically for its effects on alcohol-related behaviors. In clinical studies, JNJ-39220675 demonstrated efficacy in reducing symptoms of allergic rhinitis such as nasal congestion and total nasal symptom scores. Preclinical data suggest it may reduce alcohol intake and preference in animal models by antagonizing central H3 receptors[2][5][6][8].
- Other names
- DB12929DB-12929DB 1292941WC0AZ27V959740-39-7(4-cyclobutyl-(1,4)diazepan-1-yl)-(6-(4-fluorophenoxy)pyridin-3-yl)methanone
02
Targets
HRH3 (Histamine Receptor H3)
Beyond the preview
Go deeper on JNJ-39220675.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JNJ-39220675.